BlackRock Amends Arbutus Biopharma Stake, Maintains Passive Position
Ticker: ABUS · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | SC 13G/A |
| Filed Date | Feb 12, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still holds Arbutus Biopharma stock, signaling continued institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on February 12, 2024, indicating its ownership of Arbutus Biopharma Corp's Common Stock as of December 31, 2023. This filing updates their previous disclosure, showing BlackRock continues to hold a significant passive stake in Arbutus Biopharma. This matters to investors because BlackRock's continued substantial holding signals confidence in the company's long-term prospects, potentially influencing other institutional investors and providing a degree of stability to the stock.
Why It Matters
BlackRock's updated filing confirms its ongoing significant, passive investment in Arbutus Biopharma, which can be seen as a vote of confidence from a major institutional investor.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate change in strategy or significant risk.
Analyst Insight
Investors should note BlackRock's continued passive stake as a sign of institutional presence, but this filing alone doesn't suggest a need for immediate action. It's a routine update confirming existing investment.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Arbutus Biopharma Corp (company) — the issuer of the Common Stock
- December 31, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'Under the Securities Exchange Act of 1934 (Amendment No: 1)' sections.
Who is the subject company of this filing?
The subject company is Arbutus Biopharma Corp, as indicated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp'.
Who is the entity that filed this SC 13G/A?
The entity that filed this SC 13G/A is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement)'.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 12, 2024 regarding Arbutus Biopharma Corp (ABUS).